235 related articles for article (PubMed ID: 9315419)
1. An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9.
Mauck CK; Allen S; Baker JM; Barr SP; Abercrombie T; Archer DF
Contraception; 1997 Aug; 56(2):103-10. PubMed ID: 9315419
[TBL] [Abstract][Full Text] [Related]
2. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopy.
Mauck CK; Baker JM; Barr SP; Johanson WM; Archer DF
Contraception; 1997 Aug; 56(2):97-102. PubMed ID: 9315418
[TBL] [Abstract][Full Text] [Related]
3. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy.
Mauck CK; Baker JM; Barr SP; Abercrombie TJ; Archer DF
Contraception; 1997 Aug; 56(2):89-96. PubMed ID: 9315417
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of vaginally administered nonoxynol-9 in premenopausal women.
Barditch-Crovo P; Witter F; Hamzeh F; McPherson J; Stratton P; Alexander NJ; Trapnell CB
Contraception; 1997 Apr; 55(4):261-3. PubMed ID: 9179459
[TBL] [Abstract][Full Text] [Related]
5. Severe chemical cystitis from the transurethral intravesical insertion of a vaginal contraceptive suppository: a report of 3 cases and proposed method of management.
Mayersak JS; Viviano CJ
J Urol; 1993 Apr; 149(4):835-7. PubMed ID: 8384272
[TBL] [Abstract][Full Text] [Related]
6. Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives.
Witter FR; Barditch-Crovo P; Rocco L; Trapnell CB
Int J Gynaecol Obstet; 1999 May; 65(2):165-70. PubMed ID: 10405061
[TBL] [Abstract][Full Text] [Related]
7. Comparative trial between two soft jelly capsules containing nonoxynol as spermicidal contraceptives.
Bassol S; Recio R; de la Cruz DL
Contraception; 1989 Apr; 39(4):409-18. PubMed ID: 2541967
[TBL] [Abstract][Full Text] [Related]
8. Acceptability of two spermicides in five countries.
Raymond E; Alvarado G; Ledesma L; Diaz S; Bassol S; Morales E; Fernandez V; Carlos G
Contraception; 1999 Jul; 60(1):45-50. PubMed ID: 10549452
[TBL] [Abstract][Full Text] [Related]
9. Comparative spermicidal performance of iodinated and non-iodinated contraceptive formulations of nonoxynol-9 co-precipitated with polyvinylpyrrolidone.
Zavos PM; Correa JR; Nosek D; Mohammadi F; Digenis GA
Contraception; 1996 Jul; 54(1):39-41. PubMed ID: 8804807
[TBL] [Abstract][Full Text] [Related]
10. Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract.
Barnhart KT; Stolpen A; Pretorius ES; Malamud D
Hum Reprod; 2001 Jun; 16(6):1151-4. PubMed ID: 11387285
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of Femcap used with and without spermicide. Postcoital testing.
Mauck CK; Baker JM; Barr SP; Johanson W; Archer DF
Contraception; 1997 Aug; 56(2):111-5. PubMed ID: 9315420
[TBL] [Abstract][Full Text] [Related]
12. Effects of storage and temperature upon soft jelly capsules containing nonoxynol as spermicide.
Recio R; Bassol S
Contraception; 1995 Mar; 51(3):201-2. PubMed ID: 7621689
[TBL] [Abstract][Full Text] [Related]
13. Study of the intravaginal insert (IVI): acceptability, side effects, and post-coital spermicidal activity.
Ahmad M; Asch RH
Acta Eur Fertil; 1984; 15(5):369-76. PubMed ID: 6099026
[TBL] [Abstract][Full Text] [Related]
14. Lea's Shield: a phase I postcoital study of a new contraceptive barrier device.
Archer DF; Mauck CK; Viniegra-Sibal A; Anderson FD
Contraception; 1995 Sep; 52(3):167-73. PubMed ID: 7587188
[TBL] [Abstract][Full Text] [Related]
15. Compatibility between the spermicide nonoxynol 9 and mid-cycle human cervical mucus.
Chantler E; Hemsworth M; Roach VP; Bruce JM
Contraception; 1992 Sep; 46(3):289-95. PubMed ID: 1333387
[TBL] [Abstract][Full Text] [Related]
16. The vaginal contraceptive sponge.
Edelman DA
IPPF Med Bull; 1984 Jun; 18(3):1-2. PubMed ID: 12266284
[TBL] [Abstract][Full Text] [Related]
17. Alteration of human sperm kinematics in cervical mucus due to nonoxynol-9.
Dunmire EN; Katz DF
Contraception; 1997 Apr; 55(4):209-17. PubMed ID: 9179452
[TBL] [Abstract][Full Text] [Related]
18. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
[TBL] [Abstract][Full Text] [Related]
19. ZB-06, a vaginal film containing an engineered human contraceptive antibody (HC4-N), demonstrates safety and efficacy in a phase 1 postcoital test and safety study.
Thurman AR; Moench TR; Hoke M; Politch JA; Cabral H; Mausser E; Nador E; Morton J; Hamorsky K; Swope K; Bratcher B; Anderson DJ; Whaley KJ
Am J Obstet Gynecol; 2023 Jun; 228(6):716.e1-716.e12. PubMed ID: 36870409
[TBL] [Abstract][Full Text] [Related]
20. Acute urinary retention secondary to urethral inflammation from a vaginal contraceptive suppository in a 17-year-old boy.
Saborio DV; Kennedy WA; Hoke GP
Urol Int; 1997; 58(2):128-30. PubMed ID: 9096278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
